1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Human iPSCs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Skin
1.2.3 Blood Cells
1.3 Market by Application
1.3.1 Global Human iPSCs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Academic Research
1.3.3 Drug Development and Discovery
1.3.4 Toxicity Screening
1.3.5 Regenerative Medicine
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Human iPSCs Market Perspective (2020-2031)
2.2 Human iPSCs Growth Trends by Region
2.2.1 Global Human iPSCs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Human iPSCs Historic Market Size by Region (2020-2025)
2.2.3 Human iPSCs Forecasted Market Size by Region (2026-2031)
2.3 Human iPSCs Market Dynamics
2.3.1 Human iPSCs Industry Trends
2.3.2 Human iPSCs Market Drivers
2.3.3 Human iPSCs Market Challenges
2.3.4 Human iPSCs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Human iPSCs Players by Revenue
3.1.1 Global Top Human iPSCs Players by Revenue (2020-2025)
3.1.2 Global Human iPSCs Revenue Market Share by Players (2020-2025)
3.2 Global Human iPSCs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Human iPSCs Revenue
3.4 Global Human iPSCs Market Concentration Ratio
3.4.1 Global Human iPSCs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Human iPSCs Revenue in 2022
3.5 Human iPSCs Key Players Head office and Area Served
3.6 Key Players Human iPSCs Product Solution and Service
3.7 Date of Enter into Human iPSCs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Human iPSCs Breakdown Data by Type
4.1 Global Human iPSCs Historic Market Size by Type (2020-2025)
4.2 Global Human iPSCs Forecasted Market Size by Type (2026-2031)
5 Human iPSCs Breakdown Data by Application
5.1 Global Human iPSCs Historic Market Size by Application (2020-2025)
5.2 Global Human iPSCs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Human iPSCs Market Size (2020-2031)
6.2 North America Human iPSCs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Human iPSCs Market Size by Country (2020-2025)
6.4 North America Human iPSCs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Human iPSCs Market Size (2020-2031)
7.2 Europe Human iPSCs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Human iPSCs Market Size by Country (2020-2025)
7.4 Europe Human iPSCs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Human iPSCs Market Size (2020-2031)
8.2 Asia-Pacific Human iPSCs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Human iPSCs Market Size by Region (2020-2025)
8.4 Asia-Pacific Human iPSCs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Human iPSCs Market Size (2020-2031)
9.2 Latin America Human iPSCs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Human iPSCs Market Size by Country (2020-2025)
9.4 Latin America Human iPSCs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Human iPSCs Market Size (2020-2031)
10.2 Middle East & Africa Human iPSCs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Human iPSCs Market Size by Country (2020-2025)
10.4 Middle East & Africa Human iPSCs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Fujifilm Holding Corporation (CDI)
11.1.1 Fujifilm Holding Corporation (CDI) Company Detail
11.1.2 Fujifilm Holding Corporation (CDI) Business Overview
11.1.3 Fujifilm Holding Corporation (CDI) Human iPSCs Introduction
11.1.4 Fujifilm Holding Corporation (CDI) Revenue in Human iPSCs Business (2020-2025)
11.1.5 Fujifilm Holding Corporation (CDI) Recent Development
11.2 Ncardia
11.2.1 Ncardia Company Detail
11.2.2 Ncardia Business Overview
11.2.3 Ncardia Human iPSCs Introduction
11.2.4 Ncardia Revenue in Human iPSCs Business (2020-2025)
11.2.5 Ncardia Recent Development
11.3 Sumitomo Dainippon Pharma
11.3.1 Sumitomo Dainippon Pharma Company Detail
11.3.2 Sumitomo Dainippon Pharma Business Overview
11.3.3 Sumitomo Dainippon Pharma Human iPSCs Introduction
11.3.4 Sumitomo Dainippon Pharma Revenue in Human iPSCs Business (2020-2025)
11.3.5 Sumitomo Dainippon Pharma Recent Development
11.4 Astellas Pharma Inc
11.4.1 Astellas Pharma Inc Company Detail
11.4.2 Astellas Pharma Inc Business Overview
11.4.3 Astellas Pharma Inc Human iPSCs Introduction
11.4.4 Astellas Pharma Inc Revenue in Human iPSCs Business (2020-2025)
11.4.5 Astellas Pharma Inc Recent Development
11.5 Fate Therapeutics, Inc
11.5.1 Fate Therapeutics, Inc Company Detail
11.5.2 Fate Therapeutics, Inc Business Overview
11.5.3 Fate Therapeutics, Inc Human iPSCs Introduction
11.5.4 Fate Therapeutics, Inc Revenue in Human iPSCs Business (2020-2025)
11.5.5 Fate Therapeutics, Inc Recent Development
11.6 Pluricell Biotech
11.6.1 Pluricell Biotech Company Detail
11.6.2 Pluricell Biotech Business Overview
11.6.3 Pluricell Biotech Human iPSCs Introduction
11.6.4 Pluricell Biotech Revenue in Human iPSCs Business (2020-2025)
11.6.5 Pluricell Biotech Recent Development
11.7 Cell Inspire Biotechnology
11.7.1 Cell Inspire Biotechnology Company Detail
11.7.2 Cell Inspire Biotechnology Business Overview
11.7.3 Cell Inspire Biotechnology Human iPSCs Introduction
11.7.4 Cell Inspire Biotechnology Revenue in Human iPSCs Business (2020-2025)
11.7.5 Cell Inspire Biotechnology Recent Development
11.8 ReproCELL
11.8.1 ReproCELL Company Detail
11.8.2 ReproCELL Business Overview
11.8.3 ReproCELL Human iPSCs Introduction
11.8.4 ReproCELL Revenue in Human iPSCs Business (2020-2025)
11.8.5 ReproCELL Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Human iPSCs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Skin
Table 3. Key Players of Blood Cells
Table 4. Global Human iPSCs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Human iPSCs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Human iPSCs Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Human iPSCs Market Share by Region (2020-2025)
Table 8. Global Human iPSCs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Human iPSCs Market Share by Region (2026-2031)
Table 10. Human iPSCs Market Trends
Table 11. Human iPSCs Market Drivers
Table 12. Human iPSCs Market Challenges
Table 13. Human iPSCs Market Restraints
Table 14. Global Human iPSCs Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Human iPSCs Market Share by Players (2020-2025)
Table 16. Global Top Human iPSCs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human iPSCs as of 2022)
Table 17. Ranking of Global Top Human iPSCs Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Human iPSCs Revenue (CR5 and HHI) & (2020-2025)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Human iPSCs Product Solution and Service
Table 21. Date of Enter into Human iPSCs Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Human iPSCs Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Human iPSCs Revenue Market Share by Type (2020-2025)
Table 25. Global Human iPSCs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Human iPSCs Revenue Market Share by Type (2026-2031)
Table 27. Global Human iPSCs Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Human iPSCs Revenue Market Share by Application (2020-2025)
Table 29. Global Human iPSCs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Human iPSCs Revenue Market Share by Application (2026-2031)
Table 31. North America Human iPSCs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Human iPSCs Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Human iPSCs Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Human iPSCs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Human iPSCs Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Human iPSCs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Human iPSCs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Human iPSCs Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Human iPSCs Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Human iPSCs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Human iPSCs Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Human iPSCs Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Human iPSCs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Human iPSCs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Human iPSCs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Fujifilm Holding Corporation (CDI) Company Detail
Table 47. Fujifilm Holding Corporation (CDI) Business Overview
Table 48. Fujifilm Holding Corporation (CDI) Human iPSCs Product
Table 49. Fujifilm Holding Corporation (CDI) Revenue in Human iPSCs Business (2020-2025) & (US$ Million)
Table 50. Fujifilm Holding Corporation (CDI) Recent Development
Table 51. Ncardia Company Detail
Table 52. Ncardia Business Overview
Table 53. Ncardia Human iPSCs Product
Table 54. Ncardia Revenue in Human iPSCs Business (2020-2025) & (US$ Million)
Table 55. Ncardia Recent Development
Table 56. Sumitomo Dainippon Pharma Company Detail
Table 57. Sumitomo Dainippon Pharma Business Overview
Table 58. Sumitomo Dainippon Pharma Human iPSCs Product
Table 59. Sumitomo Dainippon Pharma Revenue in Human iPSCs Business (2020-2025) & (US$ Million)
Table 60. Sumitomo Dainippon Pharma Recent Development
Table 61. Astellas Pharma Inc Company Detail
Table 62. Astellas Pharma Inc Business Overview
Table 63. Astellas Pharma Inc Human iPSCs Product
Table 64. Astellas Pharma Inc Revenue in Human iPSCs Business (2020-2025) & (US$ Million)
Table 65. Astellas Pharma Inc Recent Development
Table 66. Fate Therapeutics, Inc Company Detail
Table 67. Fate Therapeutics, Inc Business Overview
Table 68. Fate Therapeutics, Inc Human iPSCs Product
Table 69. Fate Therapeutics, Inc Revenue in Human iPSCs Business (2020-2025) & (US$ Million)
Table 70. Fate Therapeutics, Inc Recent Development
Table 71. Pluricell Biotech Company Detail
Table 72. Pluricell Biotech Business Overview
Table 73. Pluricell Biotech Human iPSCs Product
Table 74. Pluricell Biotech Revenue in Human iPSCs Business (2020-2025) & (US$ Million)
Table 75. Pluricell Biotech Recent Development
Table 76. Cell Inspire Biotechnology Company Detail
Table 77. Cell Inspire Biotechnology Business Overview
Table 78. Cell Inspire Biotechnology Human iPSCs Product
Table 79. Cell Inspire Biotechnology Revenue in Human iPSCs Business (2020-2025) & (US$ Million)
Table 80. Cell Inspire Biotechnology Recent Development
Table 81. ReproCELL Company Detail
Table 82. ReproCELL Business Overview
Table 83. ReproCELL Human iPSCs Product
Table 84. ReproCELL Revenue in Human iPSCs Business (2020-2025) & (US$ Million)
Table 85. ReproCELL Recent Development
Table 86. Research Programs/Design for This Report
Table 87. Key Data Information from Secondary Sources
Table 88. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Human iPSCs Market Size Comparison by Type (2025-2031) & (US$ Million)
Figure 2. Global Human iPSCs Market Share by Type: 2022 VS 2029
Figure 3. Skin Features
Figure 4. Blood Cells Features
Figure 5. Global Human iPSCs Market Size Comparison by Application (2025-2031) & (US$ Million)
Figure 6. Global Human iPSCs Market Share by Application: 2022 VS 2029
Figure 7. Academic Research Case Studies
Figure 8. Drug Development and Discovery Case Studies
Figure 9. Toxicity Screening Case Studies
Figure 10. Regenerative Medicine Case Studies
Figure 11. Others Case Studies
Figure 12. Human iPSCs Report Years Considered
Figure 13. Global Human iPSCs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Human iPSCs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Human iPSCs Market Share by Region: 2022 VS 2029
Figure 16. Global Human iPSCs Market Share by Players in 2024
Figure 17. Global Top Human iPSCs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human iPSCs as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Human iPSCs Revenue in 2024
Figure 19. North America Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Human iPSCs Market Share by Country (2020-2031)
Figure 21. United States Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Human iPSCs Market Share by Country (2020-2031)
Figure 25. Germany Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Human iPSCs Market Share by Region (2020-2031)
Figure 33. China Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Human iPSCs Market Share by Country (2020-2031)
Figure 41. Mexico Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Human iPSCs Market Share by Country (2020-2031)
Figure 45. Turkey Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Human iPSCs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Fujifilm Holding Corporation (CDI) Revenue Growth Rate in Human iPSCs Business (2020-2025)
Figure 48. Ncardia Revenue Growth Rate in Human iPSCs Business (2020-2025)
Figure 49. Sumitomo Dainippon Pharma Revenue Growth Rate in Human iPSCs Business (2020-2025)
Figure 50. Astellas Pharma Inc Revenue Growth Rate in Human iPSCs Business (2020-2025)
Figure 51. Fate Therapeutics, Inc Revenue Growth Rate in Human iPSCs Business (2020-2025)
Figure 52. Pluricell Biotech Revenue Growth Rate in Human iPSCs Business (2020-2025)
Figure 53. Cell Inspire Biotechnology Revenue Growth Rate in Human iPSCs Business (2020-2025)
Figure 54. ReproCELL Revenue Growth Rate in Human iPSCs Business (2020-2025)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed

※参考情報 ヒトiPSC（ヒト誘導多能性幹細胞）は、特定の体細胞を再プログラムして作成される多能性幹細胞です。通常、体の様々な細胞は、それぞれ特定の機能と特性を持っていますが、iPSCは再プログラムによって、胚性幹細胞と同様の特性を持つことができます。これにより、iPSCは様々な細胞系統に分化する能力を持ち、再生医療や創薬、疾病モデルの構築など多岐にわたる応用が期待されています。 ヒトiPSCの概念を理解するためには、まずその定義から始めましょう。iPSCは、サイクリン、オクタミル、ソックス2、そしてレザーという4つの遺伝子を用いて作成されることが多く、これらの遺伝子は細胞の状態をバックグラウンドに戻し、幹細胞状態を再導入する役割を果たします。2006年に山中伸弥博士（Kyoto University）が初めてマウスの体細胞をiPSCに変換する手法を発表し、その後、2007年にはヒトの細胞を用いて同様の結果を得ることに成功しました。この功績により、山中博士は2012年のノーベル生理学・医学賞を受賞しました。 iPSCの特性についても重要なポイントです。まず第一に、多能性です。iPSCは、内胚葉、外胚葉、中胚葉といった三つの胚葉に由来するすべての細胞型に分化することが可能です。これにより、様々な疾患のモデル化や治療法の探索が行えるようになります。さらに、自分自身の細胞を用いて作成されるため、拒絶反応のリスクが低く、個々の患者に特有の細胞治療が可能となります。 次に、増殖能力です。iPSCは理論上、無限に増殖することができるため、多くの研究や治療に必要な代謝物質や細胞を供給することができます。この特性は、再生医療において重要な要素です。さらに、iPSCは同種の細胞を生成できるため、リソースの効率的な利用が期待されます。 iPSCには、いくつかの種類があります。一般的に、生成方法による分類が行われます。フォートシエス（Foresinked iPSCs）やエピジェネティクスを応用した種類、フィンガープリンティング技術を利用したものなど、多様な手法が開発されています。また、疾患特異的iPSCも注目されており、特定の疾患に由来する細胞を用いて病態を再現し、治療法の開発を支援する研究が進められています。 iPSCの用途は多岐にわたります。特に再生医療においては、心筋細胞や神経細胞、肝臓細胞、膵臓細胞など、様々な細胞を作成し、損傷した組織の再生や、機能回復を目指す取り組みが進んでいます。また、iPSCは創薬研究においても重要な役割を果たします。具体的には、疾患に関連する細胞系統を用いた新薬のスクリーニングや、毒性試験が行われます。これにより、従来の動物モデルに比べてよりヒトに即したデータが得られる可能性が高まります。 さらに、iPSCによる疾病モデルの構築も盛んに行われています。これにより、遺伝性疾患や神経変性疾患、がんなどのメカニズムをより深く理解し、新たな治療戦略を見出すことが可能となります。iPSCを利用することで、個別化医療の実現に向けた道が開かれています。 iPSCの研究と応用の進展に伴い、関連する技術も進化しています。特に、CRISPR/Cas9技術などの遺伝子編集技術の発展により、iPSCに対する遺伝子改変が容易になりました。これにより、特定の遺伝子の機能解析や、疾患モデルの生成が迅速に行えるようになっています。また、オルガノイド技術も注目されており、iPSCから小型の臓器を模倣した構造体を作成することが可能となり、組織の機能や相互作用を研究する新たな手段が提供されています。 最後に、iPSC研究にはいくつかの倫理的課題も存在します。特に、再生医療における細胞の利用や管理、個人の遺伝情報に関連するプライバシーの問題などが含まれます。倫理的なガイドラインを整備し、研究や医療の進展が倫理的に行われるようにすることは、今後の重要な課題です。 以上のように、ヒトiPSCは再生医療や創薬、疾病モデルの構築において革新的な可能性を秘めた細胞系であり、今後もその研究と応用が進むことが期待されています。多様な分野での応用とともに、倫理的な配慮も欠かせない重要な要素として、iPSCは今後の生物学や医療の発展に寄与していくことでしょう。

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/